A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: A Neurofibromatosis Clinical Trials Consortium study.
Ullrich, NJ; Prabhu, SP; Reddy, AT; Fisher, MJ; Packer, R; Goldman, S; Robison, NJ; Gutmann, DH; Viskochil, DH; Allen, JC; et al.
Neuro-Oncology.
2020;
22:1527-1535.
Molecular Adsorbent Recirculating System Therapy with Continuous Renal Replacement Therapy Enhanced Clearance of Piperacillin in a Pediatric Patient and Led to Failure to Attain Pharmacodynamic Targets.
Girdwood, ST; Arbough, T; Dong, M; Mizuno, T; Tang, P; Vinks, AA; Kaplan, J.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.
2020;
40:1061-1068.
Model-Informed Bayesian Estimation Improves the Prediction of Morphine Exposure in Neonates and Infants.
Euteneuer, JC; Mizuno, T; Fukuda, T; Zhao, J; Setchell, KD R; Muglia, LJ; Vinks, AA.
Therapeutic Drug Monitoring.
2020;
42:778-786.
MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase.
Taylor, ZL; Mizuno, T; Punt, NC; Baskaran, B; Sainz, AN; Shuman, W; Felicelli, N; Vinks, AA; Heldrup, J; Ramsey, LB.
Clinical Pharmacology and Therapeutics.
2020;
108:635-643.
Influence of MRP3 Genetics and Hepatic Expression Ontogeny for Morphine Disposition in Neonatal and Pediatric Patients.
Hahn, D; Fukuda, T; Euteneuer, JC; Mizuno, T; Vinks, AA; Sadhasivam, S; Emoto, C.
Journal of Clinical Pharmacology.
2020;
60:992-998.
Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric Fanconi anaemia patients.
van Hoogdalem, MW; Emoto, C; Fukuda, T; Mizuno, T; Mehta, PA; Vinks, AA.
British Journal of Clinical Pharmacology.
2020;
86:933-943.
Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease.
Bauman, LE; Xiong, Y; Mizuno, T; Minar, P; Fukuda, T; Dong, M; Rosen, MJ; Vinks, AA.
Inflammatory Bowel Diseases.
2020;
26:429-439.
Next Challenge From the Variance in Individual Physiologically-Based Pharmacokinetic Model-Predicted to Observed Morphine Concentration in Critically Ill Neonates.
Emoto, C; Hahn, D; Euteneuer, JC; Mizuno, T; Vinks, AA; Fukuda, T.
Clinical Pharmacology and Therapeutics.
2020;
107:319-320.
Electronic Health Record–Embedded Decision Support Platform for Morphine Precision Dosing in Neonates.
Vinks, AA; Punt, NC; Menke, F; Kirkendall, E; Butler, D; Duggan, TJ; Cortezzo, DE; Kiger, S; Dietrich, T; Spencer, P; et al.
Clinical Pharmacology and Therapeutics.
2020;
107:186-194.
Route of oseltamivir administration affects metabolite concentrations in critically ill children.
Tang Girdwood, SC; Mizuno, T; Krallman, KA; Benken, LA; Stoneman, EM; Yunger, TM; Wong, HR; Vinks, AA; Kaplan, JM.
The Pediatric Infectious Disease Journal.
2020;
38:1224-1227.